NR3C2 and type 1 diabetes mellitus: The comparative analysis of various RAASis suggests that monotherapy with MR antagonist eplerenone can offer equal or even superior efficacy compared to ACEis or ARBs in arresting the progression of arterial and myocardial injuries in T1DM.